{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:43:39Z","timestamp":1792590219650,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008522","name":"University of Illinois at Chicago","doi-asserted-by":"publisher","award":["SCR_020997"],"award-info":[{"award-number":["SCR_020997"]}],"id":[{"id":"10.13039\/100008522","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["T32-HL139341"],"award-info":[{"award-number":["T32-HL139341"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["129819-IRG-16-189-58-IRG-114"],"award-info":[{"award-number":["129819-IRG-16-189-58-IRG-114"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K08HL159289"],"award-info":[{"award-number":["K08HL159289"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL132906"],"award-info":[{"award-number":["HL132906"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL140589"],"award-info":[{"award-number":["R01HL140589"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010554","name":"Clinical and Translational Science Institute, University of Pittsburgh","doi-asserted-by":"publisher","award":["UL1TR002494"],"award-info":[{"award-number":["UL1TR002494"]}],"id":[{"id":"10.13039\/100010554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","award":["NCT 02891603"],"award-info":[{"award-number":["NCT 02891603"]}],"id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","award":["WO2015120436A2"],"award-info":[{"award-number":["WO2015120436A2"]}],"id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","award":["WO2017058950A1"],"award-info":[{"award-number":["WO2017058950A1"]}],"id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","award":["WO2019165156"],"award-info":[{"award-number":["WO2019165156"]}],"id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["ECCS-2025124"],"award-info":[{"award-number":["ECCS-2025124"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jtha.2023.01.027","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:16:14Z","timestamp":1675347374000},"page":"1366-1380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte\u2013endothelial proadhesive interactions"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7903-944X","authenticated-orcid":false,"given":"Joan D.","family":"Beckman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4122-0435","authenticated-orcid":false,"given":"Angelica","family":"DaSilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9713-8502","authenticated-orcid":false,"given":"Elena","family":"Aronovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aithanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geneva","family":"Hargis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1324-0831","authenticated-orcid":false,"given":"Gregory M.","family":"Vercellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-2422","authenticated-orcid":false,"given":"Brian","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-2144","authenticated-orcid":false,"given":"David K.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.01.027_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080854","article-title":"Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation","volume":"8","author":"Perner","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jtha.2023.01.027_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.027_bib3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2023.01.027_bib4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1172\/JCI133639","article-title":"The multifaceted role of ischemia\/reperfusion in sickle cell anemia","volume":"130","author":"Hebbel","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2023.01.027_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaut.2017.06.010","article-title":"Inflammation and myeloproliferative neoplasms","volume":"85","author":"Lussana","year":"2017","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jtha.2023.01.027_bib6","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.01.027_bib7","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/ATVBAHA.120.315595","article-title":"Vascular endothelial damage in the pathogenesis of organ injury in severe COVID-19","volume":"41","author":"Dupont","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.01.027_bib8","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2352-3026(20)30215-5","article-title":"Endothelial cells orchestrate COVID-19 coagulopathy","volume":"7","author":"O\u2019Sullivan","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.01.027_bib9","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1016\/S2352-3026(20)30216-7","article-title":"Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study","volume":"7","author":"Goshua","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.01.027_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3389\/fphys.2020.00989","article-title":"The enigma of endothelium in COVID-19","volume":"11","author":"Kaur","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.jtha.2023.01.027_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3233\/CH-209007","article-title":"COVID-19 and the endothelium","volume":"75","author":"Jung","year":"2020","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.jtha.2023.01.027_bib12","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/cvr\/cvaa230","article-title":"Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science","volume":"116","author":"Evans","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jtha.2023.01.027_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jth.14634","article-title":"Human endothelial cells size-select their secretory granules for exocytosis to modulate their functional output","volume":"18","author":"McCormack","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.027_bib14","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features","volume":"118","author":"Guadall","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.027_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell\u00a0expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.01.027_bib16","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1038\/onc.2017.148","article-title":"STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jtha.2023.01.027_bib17","first-page":"14","article-title":"Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability","author":"Wang","year":"2021","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.jtha.2023.01.027_bib18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.01.027_bib19","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.01.027_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bjh.14764","article-title":"Comprehensive haematological control with Ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide","volume":"182","author":"Harrison","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.01.027_bib21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The impact of Ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis","volume":"27","author":"Samuelson","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2023.01.027_bib22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.01.027_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtha.2023.01.027_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.jtha.2023.01.027_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.01.027_bib26","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cell.2020.11.007","article-title":"Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques","volume":"184","author":"Hoang","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jtha.2023.01.027_bib27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1073\/pnas.1712452115","article-title":"Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation","volume":"115","author":"Betts","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.01.027_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052449","article-title":"Thromboembolic adverse drug reactions in Janus kinase (JAK) inhibitors: does the inhibitor specificity play a role?","volume":"22","author":"Kotyla","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2023.01.027_bib29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","article-title":"Safety of Janus kinase inhibitors in older patients: A focus on the thromboembolic risk","volume":"37","author":"Rajasimhan","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jtha.2023.01.027_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.01.027_bib31","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1074\/jbc.M110.148726","article-title":"Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217","volume":"286","author":"Beckman","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.01.027_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymeth.2016.09.016","article-title":"TrackMate: an open and extensible platform for single-particle tracking","volume":"115","author":"Tinevez","year":"2017","journal-title":"Methods"},{"key":"10.1016\/j.jtha.2023.01.027_bib33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/01.ATV.19.2.290","article-title":"Urokinase activates the Jak\/Stat signal transduction pathway in human vascular endothelial cells","volume":"19","author":"Dumler","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.01.027_bib34","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0092-8674(91)90393-D","article-title":"Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins","volume":"65","author":"Lawrence","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.jtha.2023.01.027_bib35","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1073\/pnas.92.16.7450","article-title":"Platelets roll on stimulated endothelium in\u00a0vivo: an interaction mediated by endothelial P-selectin","volume":"92","author":"Frenette","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.01.027_bib36","article-title":"Absence of JAK2V617F mutated endothelial colony-forming cells in patients with JAK2V617F myeloproliferative neoplasms and splanchnic vein thrombosis","volume":"4","author":"Guy","year":"2020","journal-title":"HematologiaSphere"},{"key":"10.1016\/j.jtha.2023.01.027_bib37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/rth2.12317","article-title":"Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer","volume":"4","author":"Kasthuri","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.027_bib38","article-title":"Pro- inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis","author":"Hernandez","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.01.027_bib39","article-title":"JAK1: number one in the family; number one in inflammation?","volume":"60","author":"Spinelli","year":"2021","journal-title":"Rheumatol (Oxf Engl)"},{"key":"10.1016\/j.jtha.2023.01.027_bib40","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2015.128918","article-title":"The effects of JAK inhibitor therapy upon novel markers of thrombosis in myeloproliferative neoplasms","volume":"100","author":"Keohane","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.01.027_bib41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMe2117663","article-title":"Risks and benefits of Janus kinase inhibitors in rheumatoid arthritis\u2014past, present, and future","volume":"386","author":"Singh","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.01.027_bib42","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-021-01391-2","article-title":"Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy","volume":"35","author":"Brkic","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtha.2023.01.027_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtha.2023.01.027_bib44","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/bloodadvances.2019001379","article-title":"Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia","volume":"4","author":"Gangaraju","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.01.027_bib45","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1002\/ajh.26402","article-title":"Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients","volume":"97","author":"Reeves","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2023.01.027_bib46","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3892\/ol.2017.6459","article-title":"Clinical significance of circulating microparticles in Ph(-) myeloproliferative neoplasms","volume":"14","author":"Zhang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jtha.2023.01.027_bib47","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood.V120.21.1145.1145","article-title":"Tissue-factor bearing microparticles and thrombotic risk in the myeloproliferative neoplasms","volume":"120","author":"Stein","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.027_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222944","article-title":"Comparative phenotypic profiling of the JAK2 inhibitors Ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures","volume":"14","author":"Singer","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jtha.2023.01.027_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1242\/dmm.006817","article-title":"Mouse models of myeloproliferative neoplasms: JAK of all grades","volume":"4","author":"Li","year":"2011","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.jtha.2023.01.027_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cpph.23","article-title":"Overview of transgenic mouse models of myeloproliferative neoplasms (MPNs)","volume":"77","author":"Dunbar","year":"2017","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.jtha.2023.01.027_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092381","article-title":"Murine models of myelofibrosis","volume":"12","author":"Jacquelin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jtha.2023.01.027_bib52","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1161\/ATVBAHA.120.314760","article-title":"Platelet dysfunction and thrombosis in JAK2V617F-mutated primary myelofibrotic mice","volume":"40","author":"Matsuura","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.01.027_bib53","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/09537104.2019.1678119","article-title":"How useful are ferric chloride models of arterial thrombosis?","volume":"31","author":"Grover","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2023.01.027_bib54","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jth.14413","article-title":"Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application","volume":"17","author":"Diaz","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.01.027_bib55","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The\u00a0presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.027_bib56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2 V617F mutation","volume":"121","author":"Rosti","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.027_bib57","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.14327","article-title":"Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari syndrome without myeloproliferative neoplasm","volume":"180","author":"Helman","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.01.027_bib58","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-21-1140","article-title":"Circulating protein disulfide isomerase is associated with increased risk of thrombosis in JAK2-mutated myeloproliferative neoplasms","volume":"27","author":"Sharda","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtha.2023.01.027_bib59","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2010-07-297598","article-title":"Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms","volume":"117","author":"Teofili","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.027_bib60","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2008-12-190991","article-title":"Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker","volume":"114","author":"Piaggio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.01.027_bib61","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacbts.2019.05.013","article-title":"JAK2 (V617F)-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure","volume":"4","author":"Sano","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jtha.2023.01.027_bib62","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1158\/0008-5472.CAN-17-1098","article-title":"Persistent immune stimulation exacerbates genetically driven myeloproliferative disorders via stromal remodeling","volume":"77","author":"Tripodo","year":"2017","journal-title":"Cancer Res"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:38:01Z","timestamp":1761536281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1538783623000818"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.01.027","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte\u2013endothelial proadhesive interactions","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}